ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...
Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Normally ...
* Array Biopharma Inc - FDA informed array that based on their preliminary review of applications they have not identified any potential review issues * Array Biopharma Inc - FDA set a target action ...
Ambrosia Biosciences has launched with a $16 million series A financing round led by BVF Partners and Boulder Ventures. Ambrosia researchers are developing small-molecule, GLP-1–based drugs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results